HMG1 antibody for treating inflammatory conditions
AssigneeThe Feinstein Institute for Medical Research
InventorsKevin J. Tracey, Haichao Wang
Life of this patent
Estimating the term…
Abstract
There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
Claims19
A method for treating a disease characterized by activation of an inflammatory cytokine cascade in a subject, comprising administering to the subject an effective amount of an antibody that specifically binds to a vertebrate high mobility group 1 protein (HMG1) protein or an antigenic fragment thereof, wherein said disease is selected from the group consisting of, rheumatoid arthritis, acute pancreatitis, adult respiratory distress syndrome, reperfusion injury, inflammatory bowel disease, systemic lupus erythematosus, asthma, graft versus host disease and multiple sclerosis and wherein said antibody inhibits HMG1-mediated activation of the inflammatory cytokine cascade.
A method for treating a disease characterized by activation of an inflammatory cytokine cascade in a subject, comprising administering to the subject an effective amount an antibody fragment that specifically binds a vertebrate HMG1 protein or an antigenic fragment thereof, wherein said disease is selected from the group consisting of, rheumatoid arthritis, acute pancreatitis, adult respiratory distress syndrome, reperfusion injury, inflammatory bowel disease, systemic lupus erythematosus, asthma, graft versus host disease and multiple sclerosis and wherein said antibody fragment inhibits HMG1-mediated activation of the inflammatory cytokine cascade.
A method for treating a disease characterized by activation of an inflammatory cytokine cascade in a subject, comprising administering to the subject a pharmaceutical composition comprising an effective amount of an antibody that specifically binds to a vertebrate HMG1 protein or an antigenic fragment thereof, wherein said disease is selected from the group consisting of, rheumatoid arthritis, acute pancreatitis, adult respiratory distress syndrome, reperfusion injury, inflammatory bowel disease, systemic lupus erythematosus, asthma, graft versus host disease and multiple sclerosis and wherein said antibody inhibits HMG1-mediated activation of the inflammatory cytokine cascade.
A method for treating a disease characterized by activation of the inflammatory cytokine cascade in a subject, comprising administering to the subject a pharmaceutical composition comprising an effective amount of an antibody fragment that specifically binds a vertebrate HMG1 protein or an antigenic fragment thereof, wherein said disease is selected from the group consisting of, rheumatoid arthritis, acute pancreatitis, adult respiratory distress syndrome, reperfusion injury, inflammatory bowel disease, systemic lupus erythematosus, asthma, graft versus host disease and multiple sclerosis and wherein said antibody fragment inhibits HMG1-mediated activation of the inflammatory cytokine cascade.
Dependencies are inferred from the claim text.